Clinical and Morphological Diagnosis and Treatment of Sexually Transmitted Diseases - Yakymova, T. P. 2007

Leptotrichosis: Clinical Presentation, Morphological Types, Significance for the Patient, and Treatment

Leptotrichia is a genus of rod-shaped, non-motile, asporogenic, Gram-negative chemoorganotrophic anaerobic Bacteria belonging to the family Bacteroidaceae. They appear as straight or curved, thin or thick, long rods (1–1.5 × 5–15 μm) with slightly tapered or blunt ends, frequently arranged in long filaments. Branching is absent. Glucose is fermented with The production of acid. Reactions for indole, hydrogen sulfide, ammonia, nitrate reduction, and catalase are negative. Leptotrichia species do not form spores and possess a thick capsule. They are obligate anaerobes and can survive in ambient air for up to 72 hours. They grow on enriched culture media, such as Blood Agar, under anaerobic conditions at 35–37°C (in an atmosphere containing 10% CO₂), but fail to grow at 25°C and 45°C. Capsular Polysaccharides are a major virulence factor; during Leptotrichia infections, patients develop Antibodies directed against these capsular polysaccharides.

Leptotrichia species are essentially Gram-negative "counterparts" to E. coli, though somewhat smaller in size.

They may contain large vacuoles resembling spores. Leptotrichia filaments are significantly thinner than the pseudohyphae of Candida Fungi (0.2–0.5 μm versus 1.5–2 μm, respectively). Leptotrichia do not branch and appear either straight or curved. Filamentous and septate morphological forms are distinguished; in the latter, the septa stain similarly to the bacterial margins, making these specimens considerably thicker than the filamentous forms.

Their role in Human and Animal pathology was established in the late 19th century when leptotrichiae were isolated from necrotic lesions. At the same time, they are virtually a core component of the normal microflora, frequently dominating quantitatively in the Oral Cavity, Large Intestine, and Vagina.

Most commonly, infections involving these organisms are associated with tissue trauma and contamination by anaerobic bacteria. The direct necrotizing effect, so characteristic of Leptotrichia, is driven by their histolytic Enzymes. These enzymes break down tissue architecture, facilitating bacterial invasion and turning affected areas into expanding or abscess-forming zones of gangrenous decay.

Although occasionally part of the sparse normal vaginal microflora, Leptotrichia can become pathogenic in the presence of concurrent conditions, such as malignancies (following local radiotherapy) and surgical trauma. They contribute to The Development of pyogenic pelvic and uterine infections, including endometritis, parametritis, salpingitis, tubo-ovarian abscesses, Pelvioperitonitis, as well as post-abortal, postpartum, and postoperative phlegmons.

In most women, small numbers of Leptotrichia are present in the cervical region of the vagina; an elevated count indicates urogenital tract pathology.

Leptotrichia are also detected in chronic, complicated urethritis in men (found in 6.1% of patients with complicated post-gonococcal urethritis), particularly in those with refractory disease courses and frequent relapses.

Beyond localized tissue damage, Leptotrichia exert systemic pathogenic effects at the organismal level. These microorganisms trigger intravascular Blood Coagulation, leading to severe thrombosis, thrombophlebitis, and phlebitis. Endocarditis, ulcerative lesions of the Skin and genital mucosa, Peritonitis, and bacteremia are also frequently observed. These severe pathological manifestations contradict the opinion of certain researchers who do not consider Leptotrichia to be pathogenic.

In anaerobic pelvic infections, Leptotrichia are found in association with other anaerobic microorganisms, especially anaerobic streptococci and fusiform bacteria (Fusobacterium sp.), as well as Gram-negative aerobic enteric bacteria (see color insert, Figs. 15–19).

Successful isolation of Leptotrichia depends on proper specimen collection and transport. When pathological material can be obtained via puncture, it is drawn into a syringe and delivered to the laboratory after expelling any trapped air, as oxygen is toxic to anaerobes. Upon arrival, the laboratory inoculates Culture Media and incubates the cultures under anaerobic conditions. Concurrently, smears are prepared and stained using Pappenheim's stain, methylene blue, Gram staining, or any other appropriate method. Further isolation and identification are carried out using standard bacteriological, bacterioscopic, and serological techniques. An essential step in microbiological investigation is determining the antimicrobial susceptibility of the isolated strains.

Treatment OF LEPTOTRICHIASIS

Acute forms of the disease are treated with imidazole preparations: isoconazole (Gynotravogen) as 0.6 g vaginal suppositories, Travogen cream (0.01%); clotrimazole as 0.1 g and 0.2 g vaginal tablets, 1%–2% clotrimazole cream; miconazole—Gynodaktarin 0.1 (vaginal suppositories); econazole—Gyno-Pevaryl (0.15 g vaginal suppositories); oral imidazole derivatives—itraconazole (Sporanox) 0.1 g capsules for 3 days, ketoconazole 0.2 g tablets for 5 days, fluconazole (Diflucan) 0.05–0.15 g capsules; antifungal Antibiotics—natamycin (Pimafucin) 0.1 g tablets 4 times daily for 7–12 days, amphoglucamine 100,000 IU tablets twice daily for 10–14 days, nystatin 250,000–500,000 IU oral tablets 4–8 times daily for 14 days.

Pregnant women are managed with local therapy (clotrimazole, isoconazole, miconazole, etc.).

The detection of Leptotrichia in the absence of symptoms is not an indication for treatment, as the Organism can periodically be found in healthy individuals.

Sexual partners presenting with signs of erythematous, pruritic balanitis should be treated with topical therapies.

The criteria for a cure include the resolution of clinical symptoms and negative microbiological test results. The potential for a chronic relapsing course, reinfection, or carrier state must always be taken into consideration.

Patients are advised to abstain from sexual intercourse until cured and to use Barrier Methods of Contraception.

Pathogenetic Therapy is aimed at eliminating factors that promote disease recurrence. Where indicated, The Use of eubiotics, biogenic stimulants, Vitamins, immunomodulators, and other supportive agents is appropriate.

The first follow-up assessment is performed 1 week after completion of therapy, and the second is conducted at 4–6 weeks.